Literature DB >> 24479608

Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants.

Dalal Taha1, Sharon Kirkby, Ursula Nawab, Kevin C Dysart, Linda Genen, Jay S Greenspan, Zubair H Aghai.   

Abstract

OBJECTIVE: To determine if an early commencement of caffeine is associated with improved survival without bronchopulmonary dysplasia (BPD) in preterm infants.
METHODS: Retrospective data analysis from the Alere Neonatal Database for infants weighing ≤1250 g, and treated with caffeine within the first 10 days of life. The neonatal outcomes were compared between the infants who received early caffeine (0-2 days) with the infants who received delayed caffeine (3-10 days).
RESULTS: A total of 2951 infants met the inclusion criteria (early caffeine 1986, late caffeine 965). The early use of caffeine was associated with reduction in BPD (OR 0.69, 95% CI 0.58-0.82, p < 0.001) and BPD or death (OR 0.77, 95% CI 0.63-0.94, p = 0.01). Other respiratory outcomes also improved with the early commencement of caffeine. The frequency of severe intraventricular hemorrhage and patent ductus arteriosus was lower and the length of hospitalization was shorter in infants receiving early caffeine therapy. However, early use of caffeine was associated with an increase in the risk of nectrotizing enterocolits (NEC) (OR 1.41, 95% CI 1.04-1.91, p = 0.027).
CONCLUSION: Early commencement of caffeine was associated with improvement in survival without BPD in preterm infants. The risk of NEC with early caffeine use requires further investigation.

Entities:  

Keywords:  BPD; NEC; neonates; premature; xanthine

Mesh:

Substances:

Year:  2014        PMID: 24479608     DOI: 10.3109/14767058.2014.885941

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  27 in total

1.  Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU.

Authors:  T D Nelin; E Pena; T Giacomazzi; S Lee; J W Logan; M Moallem; R Bapat; E G Shepherd; L D Nelin
Journal:  J Perinatol       Date:  2017-06-15       Impact factor: 2.521

Review 2.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

Review 3.  Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review.

Authors:  Sandra Nylander Vujovic; Chiara Nava; Minna Johansson; Matteo Bruschettini
Journal:  Pediatr Res       Date:  2020-01-13       Impact factor: 3.756

Review 4.  The Role of Caffeine in Noninvasive Respiratory Support.

Authors:  Nicole R Dobson; Ravi Mangal Patel
Journal:  Clin Perinatol       Date:  2016-09-28       Impact factor: 3.430

5.  Caffeine Protects Against Anticonvulsant-Induced Neurotoxicity in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Marco Sifringer; Ivo Bendix; Christoph Bührer
Journal:  Neurotox Res       Date:  2017-06-22       Impact factor: 3.911

6.  Evaluation of Timing and Dosing of Caffeine Citrate in Preterm Neonates for the Prevention of Bronchopulmonary Dysplasia.

Authors:  Eleni E Shenk; Deborah S Bondi; Matthew M Pellerite; Sudhir Sriram
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

Review 7.  Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates.

Authors:  Kok Pim Kua; Shaun Wen Huey Lee
Journal:  Br J Clin Pharmacol       Date:  2016-09-30       Impact factor: 4.335

Review 8.  Caffeine therapy in preterm infants.

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 9.  Preventing Continuous Positive Airway Pressure Failure: Evidence-Based and Physiologically Sound Practices from Delivery Room to the Neonatal Intensive Care Unit.

Authors:  Clyde J Wright; Laurie G Sherlock; Rakesh Sahni; Richard A Polin
Journal:  Clin Perinatol       Date:  2018-02-28       Impact factor: 3.430

10.  Caffeine Protects Against Anticonvulsant-Induced Impaired Neurogenesis in the Developing Rat Brain.

Authors:  Stefanie Endesfelder; Ulrike Weichelt; Cornelia Schiller; Katja Winter; Clarissa von Haefen; Christoph Bührer
Journal:  Neurotox Res       Date:  2018-02-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.